14.11.2019 | Insight

‘A new hope’ found in the FDA approvals of Entresto and Farxiga

By Nathan Cripps

A new hope’ found in the FDA approvals of Entresto and Farxiga

CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens. The FDA approved over 300 submissions within the month of October which included medication for cystic fibrosis, ulcerative colitis and HIV.

The most mentioned FDA approvals by HCPs online

BrandCompound(s)ManufacturerBrand mentionsCompound mentionsTotal mentions
Descovyemtricitabine; tenofovir alafenamide fumarateGilead Sciences591271
Entrestosacubitril; valsartanNovartis164662
Trikaftaelexacaftor, tezacaftor, ivacaftorVertex56056
Reyvowlasmiditan succinateEli Lilly And Co03232
Asenapineasenapine maleateSigmapharm Labs Llc111122
Naftifinenaftifine hydrochlorideTaro21021
RisperidonearisperidoneZydus Pharms Usa Inc18119
Fiaspinsulin aspartNovo Nordisk6814
SecuadoasenapineHisamitsu Pharm Co01111
AmzeeqminocyclineFoamix Pharma Inc3811
Zejulaniraparib tosylateTesaro Inc01111
SubsysfentanylBtcp Pharma7310
Suboxonebuprenorphine hydrochloride; naloxone hydrochlorideIndivior Inc189
Vytorinezetimibe; simvastatinMsd Intl808
Biorphenphenylephrine hydrochlorideSintetica Sa358
Quzyttircetirizine hydrochlorideJdp Therapeutics Inc077
Xofluzabaloxavir marboxilGenentech Inc077
Baxdeladelafloxacin meglumineMelinta257
RanexaranolazineGilead Sciences707
AklieftrifaroteneGalderma Research And Development Llc336
CarbidopaacarbidopaAurobindo Pharma Ltd066
Sildenafilsildenafil citratePerrigo R And D505

The most mentioned approval this month, with 71 mentions, was Gilead’s Descovy (emtricitabine + tenofavir). This was approved for the use in HIV prophylaxis for men and transgender women however, HCPs raised concerns and suggested a need for more inclusive trials. Even with this concern HCPs are positive towards the approval saying that it is a ’big win for the HIV community’ and ‘BIG news for patients’.


The second most mentioned product in October, was AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) for their new indication to reduce heart failure (HF) in type 2 diabetes patients. This news was shared 67 times by HCPs during October with one pharmacist, Diana Isaacs in Cleveland, Ohio, sharing her excitement for the approval in a post well engaged by her peers.


HCPs were positive about the approval of Novartis’ Entresto (sacubitril/valsartan) for use in treating dilated cardiomyopathy (DCM) and HF in children describing it as ‘a new hope’. Collectively, they shared this news 62 times, making it the third most mentioned product this month.


We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge, or by signing up to our monthly eJournal.



Methodology notes:

  • Data for this research was analysed from the online Twitter conversations of HCPs talking about FDA approvals in English language (all other languages are available), between October 1st and October 31th 2019.
  • Between October 1st and October 31th 2019, 1,459 HCPs posted about FDA approvals 1,904 times all over the world.
  • HCPs mention brand and compound names when discussing FDA approvals. Approvals may include multiple compounds. 

View all articles >

Meet the Author

Nathan Cripps

Suggested next

How do doctors' conversations differ from private to public networks?

19.02.2018 | Article

How do doctors’ conversations differ from private to public networks?

How do doctors' conversations differ from private to public networks?

By Jamie Doggett

HCPs quick to forgive Celgene’s advert

20.06.2019 | Article

HCPs quick to forgive Celgene’s advert

During the European Haematology Association 2019 Congress, Celgene released what healthcare

By Mary Kangley

View all articles >